Site for COG AALL1731 A Phase 3 Trial Investigating Blinatumomab (IND# 117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients wi

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Standard Risk Or Down Syndrome B Lymphoblastic Leukemia (b-all) And Localized B-lymphoblastic Lymphoma (b-lly)
  • Age: Between 1 Year(s) - 31 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) B-ALL patients without DS must have an initial white blood cell count <50,000/µL. 2) B-ALL patients with DS are eligible regardless of the presenting white blood cell count.

You may not be eligible for this study if the following are true:

  • 1) Patient must not have secondary ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy. 2) Patient must not have acute undifferentiated leukemia(AUL

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.